First patient enrolled in NG11-2 Phase Ib clinical trial Gallery First patient enrolled in NG11-2 Phase Ib clinical trial By Chloe Atkinson|2025-05-20T09:39:27+00:00May 8th, 2023|Clinical Development, News, NG11| Read More
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial Gallery VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial By Chloe Atkinson|2025-05-20T09:39:11+00:00January 24th, 2023|Clinical Development, News, NG11| Read More
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology Gallery VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology By Chloe Atkinson|2025-05-20T09:36:31+00:00December 22nd, 2022|Clinical Development, News| Read More
VasoDynamics submits UK Clinical Trial Application for NG11-2 Gallery VasoDynamics submits UK Clinical Trial Application for NG11-2 By Chloe Atkinson|2025-05-20T09:38:29+00:00October 21st, 2022|Clinical Development, News, NG11| Read More
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production Gallery VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production By Chloe Atkinson|2025-05-20T09:36:43+00:00March 5th, 2022|Clinical Development, News, NG11| Read More
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development Gallery VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development By Chloe Atkinson|2025-05-20T09:37:06+00:00September 21st, 2021|Clinical Development, News, NG11| Read More
